NCT06380517招募中3 期
A Randomized Trial of Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Jaeb Center for Health Research127 个研究点 分布在 1 个国家目标入组 238 人开始时间: 2024年7月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 238
- 试验地点
- 127
- 主要终点
- Change in amblyopic eye logMAR distance VA between randomization and 26 weeks
研究概览
简要总结
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
详细描述
Participants eligible for the study will be randomly allocated (1:1) to receive either dichoptic treatment while wearing the Luminopia headset or patching treatment of the fellow eye for amblyopia with clinical assessments at 13, and 26-weeks post-randomization.
At the 26-week primary outcome visit, participants who were randomly assigned to receive patching treatment with an IOD of 1 logMAR line or more, will be offered Luminopia dichoptic therapy and if they accept, followed forward with visits at 39- and 52-weeks post-randomization.
The study will end for all other participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 4 Years 至 7 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •to be eligible to participate in the study.
- •Age 4 to 7 years.
- •Visual acuity, measured in each eye without cycloplegia in current refractive correction (if applicable) using the ATS-HOTV VA protocol on a study-approved device displaying single surrounded optotypes, as follows:
- •VA in the amblyopic eye 20/40 to 20/200 inclusive.
- •Age-normal VA in the fellow eye:44,45
- •4 years: 20/40 or better; 5-6 years: 20/32 or better; 7 years: 20/25 or better
- •Interocular difference ≥ 3 logMAR lines (i.e., amblyopic eye VA at least 3 logMAR lines worse than fellow eye VA).
- •Amblyopia associated with strabismus, anisometropia, or both (previously treated or untreated).
- •Criteria for strabismic amblyopia: At least one of the following must be met:
- •Presence of a heterotropia on examination at distance or near fixation (with optical correction), must be <=5 prism diopters (∆) by SPCT at distance and near fixation (see #7 below).
- •Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia).
- •Criteria for anisometropia: At least one of the following criteria must be met:
- •≥1.00 D difference between eyes in spherical equivalent (SE).
- •≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
- •Criteria for combined-mechanism: Both of the following criteria must be met:
- •A criterion for strabismus is met (see above).
- •≥1.00 D difference between eyes in spherical equivalent OR ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes.
- •No more than 2 weeks (cumulative) of prior dichoptic treatment.
- •No treatment with cycloplegic eyedrops (e.g., atropine) in the past 2 weeks; other treatments allowed up to enrollment but then must be discontinued.
- •Refractive correction is required (single vision lenses or contact lenses) for any of the following refractive errors based on a cycloplegic refraction completed within the last 7 months:
- •Hypermetropia of 2.50 D or more by SE
- •Myopia of amblyopic eye of 0.50D or more SE
- •Astigmatism of 1.00D or more
- •Anisometropia of more than 0.50D SE
- •NOTE: Monocular or binocular contact lens wear is allowed provided the contact lenses meet the refractive error correction requirements below. For each child, all testing must be performed using the same form of optical correction (i.e., no changing between contacts and spectacles).
- •Spectacles/contact lens correction prescribing instructions referenced to the cycloplegic refraction completed within the last 7 months:
- •SE must be within 0.50D of fully correcting the anisometropia (if new glasses are prescribed, reduction in plus sphere must be symmetric in the two eyes).
- •SE must not be under corrected by more than 1.50D SE.
- •Cylinder power in both eyes must be within 0.50D of fully correcting the astigmatism.
- •Axis must be within +/- 10 degrees if cylinder power is ≤1.00D, and within +/- 5 degrees if cylinder power is >1.00D.
- •Myopia must not be under corrected by more than 0.25D or over corrected by more than 0.50D SE, and any change must be symmetrical in the two eyes.
- •Spectacles/contact lens correction (with or without other treatment such as patching) meeting the above criteria must be worn:
- •For at least 18 weeks OR until VA stability is documented (defined as <0.1 logMAR change by the same testing method measured on 2 consecutive exams at least 9 weeks apart).
- •For determining VA stability (non-improvement):
- •The first of two measurements may be made 1) in current correction, or 2) in trial frames with or without cycloplegia or 3) without correction (if new correction is prescribed),
- •The second measurement must be made without cycloplegia in the correct spectacles/contact lens correction that has been worn for at least 9 weeks.
- •NOTE: Because this determination is a pre-randomization, the method of measuring VA is not mandated.
- •Participant is willing to wear the Luminopia headset.
- •Participant is willing to continue full-time spectacles/contact lens wear (if needed).
- •Participant is willing to accept assignment to either dichoptic shows (view 1 hour per day 6 days per week) OR part-time patching (2 hours per day 7 days per week) for 26 weeks.
- •Interpupillary distance of 52mm to 72mm inclusive.
- •Investigator is willing to prescribe Luminopia or patching per protocol.
- •Parent understands the protocol and is willing to accept randomization.
- •Parent has phone (or access to phone) and is willing to be contacted by JAEB Center.
- •Relocation outside area of active PEDIG site within the next 52 weeks is not anticipated.
- •Individuals meeting any of the following criteria will be excluded from study participation.
- •Heterotropia more than 5∆ at distance or near (measured by SPCT in current correction)
- •Prism lenses or need of a prism prescription at enrollment.
- •Current bifocal spectacles (eligible only if bifocal discontinued 2 weeks prior to enrollment).
- •Myopia greater than -6.00D spherical equivalent in either eye.
- 另有 8 项未显示
排除标准
- 未提供
研究组 & 干预措施
Luminopia Group
Experimental
watching dichoptic movies/shows wearing the Luminopia headset prescribed 1 hour per day (treatment time can be split into shorter sessions totaling 1 hour each day) 6 days a week with optical correction, if needed.
干预措施: Luminopia (Device)
Patching Group
Active Comparator
patching of the fellow eye 2 hours per day (treatment time can be split into shorter sessions totaling 2 hours each day) 7 days per week with optical correction, if needed.
干预措施: Eye Patch (Other)
结局指标
主要结局
Change in amblyopic eye logMAR distance VA between randomization and 26 weeks
时间窗: 26 Weeks
次要结局
未报告次要终点
研究者
研究点 (127)
Loading locations...
相似试验
已完成
2 期
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR MutationsAttention Deficit Hyperactivity DisorderNCT03265119Aevi Genomic Medicine, LLC, a Cerecor company69
终止
3 期
Combined Patching-Atropine for Residual AmblyopiaAmblyopiaNCT00506675Jaeb Center for Health Research55
已完成
3 期
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)Pulmonary Disease, Chronic ObstructiveNCT02006732Boehringer Ingelheim809
已完成
3 期
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)Pulmonary Disease, Chronic ObstructiveNCT01964352Boehringer Ingelheim813
已完成
3 期
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With AsthmaAsthmaNCT00441441GlaxoSmithKline351